Different clinical relevance of anti-citrullinated proteins antibodies in RA patients
Objective – to find a potential relationship between ACPA and disease activity, bone destruction, and ACPAs responses to various therapeutic regimens.Materials and methods. The study included 232 patients with rheumatoid arthritis (RA); 90 patients had early RA; 142 patients had advanced stage of th...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2022-05-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3151 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849240400803397632 |
|---|---|
| author | A. S. Avdeeva M. V. Cherkasova E. L. Nasonov |
| author_facet | A. S. Avdeeva M. V. Cherkasova E. L. Nasonov |
| author_sort | A. S. Avdeeva |
| collection | DOAJ |
| description | Objective – to find a potential relationship between ACPA and disease activity, bone destruction, and ACPAs responses to various therapeutic regimens.Materials and methods. The study included 232 patients with rheumatoid arthritis (RA); 90 patients had early RA; 142 patients had advanced stage of the disease.Results. 77 (85.6%) patients with early RA were high positive for anti-CCP, and 29 (70.7%) patients – high positive for anti-MCV. A positive correlation was found between anti-MCV and DAS28 (r=0.4; p=0.04). As for advanced RA, 78 (80.4%) patients were high positive for anti-CCP, and 70 (79.5%) – for anti-MCV. There was a positive correlation between anti-MCV concentration and SDAI (r=0.4; p=0.02), as well as CDAI (r=0.4; p=0.02). No significant correlations were found between the anti-CCP levels and activity indices, anti-CCP and acute-phase parameters in both early and advanced RA groups. Higher total Sharp scores (96.5 (65.0–122.0)) were found in pts high positive for anti-MCV (n=79), compared to low-positive/negative (n=27) patients (57.0 (31.0–88.0); p<0.05). Anti-MCV levels dropped significantly in pts on rituximab and tocilizumab therapy at weeks 12 and 24 after initiation of treatment, while high anti-CCP concentration persisted throughout the treatment.Conclusion. Anti-MCV levels correlated with inflammatory activity and development of bone destruction, and were decreasing in pts on treatment. Anti-CCP was less responsive, showed minor changes during treatment, therefore its’ thorough monitoring was not feasible. |
| format | Article |
| id | doaj-art-ba845f736f4a4673acaca66ce5cd6f5e |
| institution | Kabale University |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2022-05-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-ba845f736f4a4673acaca66ce5cd6f5e2025-08-20T04:00:38ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922022-05-0160218118710.47360/1995-4484-2022-181-1872795Different clinical relevance of anti-citrullinated proteins antibodies in RA patientsA. S. Avdeeva0M. V. Cherkasova1E. L. Nasonov2V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Objective – to find a potential relationship between ACPA and disease activity, bone destruction, and ACPAs responses to various therapeutic regimens.Materials and methods. The study included 232 patients with rheumatoid arthritis (RA); 90 patients had early RA; 142 patients had advanced stage of the disease.Results. 77 (85.6%) patients with early RA were high positive for anti-CCP, and 29 (70.7%) patients – high positive for anti-MCV. A positive correlation was found between anti-MCV and DAS28 (r=0.4; p=0.04). As for advanced RA, 78 (80.4%) patients were high positive for anti-CCP, and 70 (79.5%) – for anti-MCV. There was a positive correlation between anti-MCV concentration and SDAI (r=0.4; p=0.02), as well as CDAI (r=0.4; p=0.02). No significant correlations were found between the anti-CCP levels and activity indices, anti-CCP and acute-phase parameters in both early and advanced RA groups. Higher total Sharp scores (96.5 (65.0–122.0)) were found in pts high positive for anti-MCV (n=79), compared to low-positive/negative (n=27) patients (57.0 (31.0–88.0); p<0.05). Anti-MCV levels dropped significantly in pts on rituximab and tocilizumab therapy at weeks 12 and 24 after initiation of treatment, while high anti-CCP concentration persisted throughout the treatment.Conclusion. Anti-MCV levels correlated with inflammatory activity and development of bone destruction, and were decreasing in pts on treatment. Anti-CCP was less responsive, showed minor changes during treatment, therefore its’ thorough monitoring was not feasible.https://rsp.mediar-press.net/rsp/article/view/3151rheumatoid arthritisdisease activitybone destructionanti-citrullinated proteins antibodies |
| spellingShingle | A. S. Avdeeva M. V. Cherkasova E. L. Nasonov Different clinical relevance of anti-citrullinated proteins antibodies in RA patients Научно-практическая ревматология rheumatoid arthritis disease activity bone destruction anti-citrullinated proteins antibodies |
| title | Different clinical relevance of anti-citrullinated proteins antibodies in RA patients |
| title_full | Different clinical relevance of anti-citrullinated proteins antibodies in RA patients |
| title_fullStr | Different clinical relevance of anti-citrullinated proteins antibodies in RA patients |
| title_full_unstemmed | Different clinical relevance of anti-citrullinated proteins antibodies in RA patients |
| title_short | Different clinical relevance of anti-citrullinated proteins antibodies in RA patients |
| title_sort | different clinical relevance of anti citrullinated proteins antibodies in ra patients |
| topic | rheumatoid arthritis disease activity bone destruction anti-citrullinated proteins antibodies |
| url | https://rsp.mediar-press.net/rsp/article/view/3151 |
| work_keys_str_mv | AT asavdeeva differentclinicalrelevanceofanticitrullinatedproteinsantibodiesinrapatients AT mvcherkasova differentclinicalrelevanceofanticitrullinatedproteinsantibodiesinrapatients AT elnasonov differentclinicalrelevanceofanticitrullinatedproteinsantibodiesinrapatients |